Scholars Central

Search Scholars Central

Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.

Advanced searchHide advanced search

In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:

Years

1–25 of 95 articles for Pembrolizumab

Then save them, add them to a collection or cite them together.
  1. Case report · 27 Feb 2022

    Pembrolizumab as a First Line Therapy in a Patient with Extensive Mucoepidermoid Salivary Gland Carcinoma: A Complete Clinical, Radiological And Pathological Response: A Very Specific Case

    Clinical Oncology: Case Reports · Volume 5, Issue 2

    various entities not limited to non-small cell lung cancer and malignant melanoma. Pembrolizumab, an anti-PD-1 antibody, has been proven to have strong anti-tumor activity ... unique case of advanced high grade…

  2. Article · 23 Jan 2026

    Marked Response after One Cycle of Pembrolizumab Monotherapy for Non-small Cell Lung Cancer: A Case Report and Brief Review of the Literature

    Oncology & Cancer Case Reports · Volume 11, Issue 4

    reports of Non-Small Cell Lung Cancer (NSCLC) cases where a single cycle of pembrolizumab monotherapy led to near-complete tumor resolution without any adverse events. Case Presentation ... high Programmed Cell Death…

  3. Case report · 21 Sep 2023

    Acute interstitial nephritis after treatment with pembrolizumab in a patient with triple negative breast cancer: a case report

    Clinical Oncology: Case Reports · Volume 6, Issue 9

    Pembrolizumab is a humanized monoclonal antibody targeting the anti-Programmed Cell Death 1 (PD-1) receptor expressed on the surface of cytotoxic T lymphocytes. Currently the introduction of immunotherapy ... study. We…

  4. Conference abstract · 2 Nov 2017

    Type and frequency of immune-related adverse reactions in patients treated with Pembrolizumab, a monoclonal antibody directed against PD-1, in advanced melanoma at Mayo Clinic in Jacksonville, Florida (or a single institution?)

    Journal of Clinical and Cellular Immunology

    these medications can trigger immune-related adverse reactions. Documented immune-related adverse reactions of pembrolizumab include pneumonitis, immune-mediated colitis, hepatitis, endocrinopathies, and nephritis. The…

  5. Research article · 10 Jun 2020

    Detection and evaluation of ELISA analysis for the circulating cancers sera antigens by monoclonal antibody UNIVmAB and pembrolizumAB.

    Allied Journal of Medical Research · Volume 4, Issue 2

    ELISA for an antigen detected by a specific monoclonal antibody, named UNIVmAb and with pembrolizumAb for comparison in all human cancers of different grades. This first method is based ... classification along with…

  6. Research article · 28 Oct 2024

    A Multistrike Evolutionary Oncology Strategy for Locally Advanced Pancreatic Cancer: A Phase 1 Trial of Standard-of-Care Plus Irreversible Electroporation and Pembrolizumab Immunotherapy

    Journal of Clinical Trials · Volume 14, Issue 6

    LAPC. The treatment involves a nonconcurrent combination of CHT, RT, IRE, and IO with pembrolizumab. The study assesses the safety, tolerability, and preliminary efficacy of this combined sequential therapy. Biopsies

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels